Imugene Ltd IMU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMU is a good fit for your portfolio.
News
-
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
-
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
-
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment
-
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
Trading Information
- Previous Close Price
- A$0.09
- Day Range
- A$0.08–0.09
- 52-Week Range
- A$0.04–0.15
- Bid/Ask
- A$0.08 / A$0.08
- Market Cap
- A$628.41 Mil
- Volume/Avg
- 24.6 Mil / 16.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 5
- Website
- https://www.imugene.com
Comparables
Valuation
|
Metric
|
IMU
|
TNG
|
SGEN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.09 | 8.01 | 16.92 |
Price/Sales | — | 105.34 | 18.61 |
Price/Cash Flow | — | — | — |
Price/Earnings
IMU
TNG
SGEN
Financial Strength
|
Metric
|
IMU
|
TNG
|
SGEN
|
|---|---|---|---|
Quick Ratio | 5.46 | 1.70 | 1.96 |
Current Ratio | 5.73 | 1.79 | 2.67 |
Interest Coverage | — | −131.90 | — |
Quick Ratio
IMU
TNG
SGEN
Profitability
|
Metric
|
IMU
|
TNG
|
SGEN
|
|---|---|---|---|
Return on Assets (Normalized) | — | −48.94% | −13.05% |
Return on Equity (Normalized) | — | −86.44% | −17.35% |
Return on Invested Capital (Normalized) | — | −79.12% | −16.86% |
Return on Assets
IMU
TNG
SGEN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rjcbmlrkh | Dxmkz | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nqvwzwmf | Szxtyw | $101.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ynldtcgw | Hsmfk | $98.1 Bil | |
MRNA
| Moderna Inc | Dbypnzr | Hcns | $42.2 Bil | |
ARGX
| argenx SE ADR | Nwnbkvny | Hbtg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nljqjpcj | Rxxjf | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wdvcyzbf | Spcsgl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tyqfnnjy | Fzwxwgn | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ybgwbxylw | Vtzbpr | $12.5 Bil | |
INCY
| Incyte Corp | Jkpgdrms | Xpktks | $11.7 Bil |